Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance

Journal of Immunology

Volumn 179, Issue 10, 2007, Pages 6620-6629

  Thornley, Thomas B ^a   Phillips, Nancy E ^a   Beaudette Zlatanova, Britte C ^a   Markees, Thomas G ^a   Bahl, Kapil ^a   Brehm, Michael A ^a   Shultz, Leonard D ^b   Kurt Jones, Evelyn A ^a   Mordes, John P ^a   Welsh, Raymond M ^a   Rossini, Aldo A ^a   Greiner, Dale L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; INTERFERON; LIGAND; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; ALPHA BETA INTERFERON RECEPTOR; INTERFERON INDUCING AGENT; MYD88 PROTEIN, MOUSE; MYELOID DIFFERENTIATION FACTOR 88; POLYINOSINIC POLYCYTIDYLIC ACID; TLR3 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; GRAFT SURVIVAL; IMMUNE RESPONSE; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ALLOGRAFT; TRANSPLANTATION TOLERANCE; ALLOTRANSPLANTATION; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; MOUSE MUTANT; SIGNAL TRANSDUCTION; SKIN TRANSPLANTATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; GRAFT SURVIVAL; IMMUNITY, NATURAL; INTERFERON INDUCERS; INTERFERON TYPE I; LIPOPOLYSACCHARIDES; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; POLY I-C; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; SKIN TRANSPLANTATION; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 38449109678     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.10.6620     Document Type: Article

References (56)

1. Akira, S. 2006. TLR signaling. Curr. Top. Microbiol. Immunol. 311: 1-16.
2. Beutler, B., Z. Jiang, P. Georgel, K. Crozat, B. Croker, S. Rutschmann, X. Du, and K. Hoebe. 2006. Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 24: 353-389.
3. Wagner, H. 2006. Endogenous TLR ligands and autoimmunity. Adv. Immunol. 91: 159-173.
4. Hoebe, K., Z. Jiang, K. Tabeta, X. Du, P. Georgel, K. Crozat, and B. Beutler. 2006. Genetic analysis of innate immunity. Adv. Immunol. 91: 175-226.
5. Marshak-Rothstein, A. 2006. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6: 823-835.
6. Obhrai, J., and D. R. Goldstein. 2006. The role of toll-like receptors in solid organ transplantation. Transplantation 81: 497-502.
7. Goldstein, D. R. 2004. Toll-like receptors and other links between innate and acquired alloimmunity. Curr. Opin. Immunol. 16: 538-544.
8. Rossini, A. A., D. L. Greiner, and J. P. Mordes. 1999. Induction of immunological tolerance for transplantation. Physiol. Rev. 79: 99-141.
9. Forman, D., R. M. Welsh, T. G. Markees, B. A. Woda, J. P. Mordes, A. A. Rossini, and D. L. Greiner. 2002. Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms. J. Immunol. 168: 6047-6056.
10. Welsh, R. M., T. G. Markees, B. A. Woda, K. A. Daniels, M. A. Brehm, J. P. Mordes, D. L. Greiner, and A. A. Rossini. 2000. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J. Virol. 74: 2210-2218.
11. Adams, A. B., M. A. Williams, T. R. Jones, N. Shirasugi, M. M. Durham, S. M. Kaech, E. J. Wherry, T. Onami, J. G. Lanier, K. E. Kokko, et al. 2003. Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest. 111: 1887-1895.
12. Chen, L., T. Wang, P. Zhou, L. Ma, D. Yin, J. Shen, L. Molinero, T. Nozaki, T. Phillips, S. Uematsu, et al. 2006. TLR engagement prevents transplantation tolerance. Am. J. Transplant. 6: 2282-2291.
13. Thornley, T. B., M. A. Brehm, T. G. Markees, L. D. Shultz, J. P. Mordes, R. M. Welsh, A. A. Rossini, and D. L. Greiner. 2006. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J. Immunol. 176: 1561-1570.
14. Snanoudj, R., H. de Preneuf, C. Creput, N. Arzouk, B. Deroure, S. Beaudreuil, A. Durrbach, and B. Charpentier. 2006. Costimulation blockade and its possible future use in clinical transplantation. Transplant. Int. 19: 693-704.
15. Larsen, C. P., S. J. Knechtle, A. Adams, T. Pearson, and A. D. Kirk. 2006. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am. J. Transplant. 6: 876-883.
16. Parker, D. C., D. L. Greiner, N. E. Phillips, M. C. Appel, A. W. Steele, F. H. Durie, R. J. Noelle, J. P. Mordes, and A. A. Rossini. 1995. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA 92: 9560-9564.
17. + T cells, interferon-γ, and CTLA4. J. Clin. Invest. 101: 2446-2455.
18. Kenyon, N. S., L. A. Fernandez, R. Lehmann, M. Masetti, A. Ranuncoli, M. Chatzipetrou, G. Iaria, D. M. Han, J. L. Wagner, P. Ruiz, et al. 1999. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 48: 1473-1481.
19. Kenyon, N. S., M. Chatzipetrou, M. Masetti, A. Ranuncoli, M. Oliveira, J. L. Wagner, A. D. Kirk, D. M. Harlan, L. C. Burkly, and C. Ricordi. 1999. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc. Natl. Acad. Sci. USA 96: 8132-8137.
20. + T cells and prolonged graft survival in a CTLA4-dependent manner. J. Immunol. 164: 512-521.
21. Li, Y. S., X. C. Li, X. X. Zheng, A. D. Wells, L. A. Turka, and T. B. Strom. 1999. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5: 1298-1302.
22. Wells, A. D., X. C. Li, Y. S. Li, M. C. Walsh, X. X. Zheng, Z. H. Wu, G. Nuñez, A. M. Tang, M. Sayegh, W. W. Hancock, et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5: 1303-1307.
23. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.
24. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150.
25. Muller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
26. Iwakoshi, N. N., T. G. Markees, N. A. Turgeon, T. Thornley, A. Cuthbert, J. H. Leif, N. E. Phillips, J. P. Mordes, D. L. Greiner, and A. A. Rossini. 2001. Skin allograft maintenance in a new synchimeric model system of tolerance. J. Immunol. 167: 6623-6630.
27. b-specific cytotoxic T cell clone detect several clone-specific molecules. J. Immunol. 136: 1937-1944.
28. Rubinstein, S., P. C. Familletti, and S. Pestka. 1981. Convenient assay for interferons. J. Virol. 37: 755-758.
29. Brehm, M. A., K. A. Daniels, J. R. Ortaldo, and R. M. Welsh. 2005. Rapid conversion of effector mechanisms from NK to T cells during virus-induced lysis of allogeneic implants in vivo. J. Immunol. 174: 6663-6671.
30. Brehm, M. A., J. Mangada, T. G. Markees, T. Pearson, K. A. Daniels, T. B. Thornley, R. M. Welsh, A. A. Rossini, and D. L. Greiner. 2007. Rapid quantification of naive alloreactive T cells by TNF-α production and correlation with allograft rejection in mice. Blood 109: 819-826.
31. Tesar, B. M., J. Zhang, Q. Li, and D. R. Goldstein. 2004. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Toll-like receptor signal adaptor protein. Am. J. Transplant. 4: 1429-1439.
32. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413: 732-738.
33. Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira, and T. Fujita. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5: 730-737.
34. Kang, D. C., R. V. Gopalkrishnan, Q. Wu, E. Jankowsky, A. M. Pyle, and P. B. Fisher. 2002. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl. Acad. Sci. USA 99: 637-642.
35. Saunders, L. R., and G. N. Barber. 2003. The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J. 17: 961-983.
36. Hoshino, K., T. Kaisho, T. Iwabe, O. Takeuchi, and S. Akira. 2002. Differential involvement of IFN-β in Toll-like receptor-stimulated dendritic cell activation. Int. Immunol. 14: 1225-1231.
37. Walker, W. E., I. W. Nasr, G. Camirand, B. M. Tesar, C. J. Booth, and D. R. Goldstein. 2006. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J. Immunol. 177: 5307-5316.
38. Bettelli, E., Y. J. Carrier, W. D. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
39. Graca, L., K. Honey, E. Adams, S. P. Cobbold, and H. Waldmann. 2000. Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J. Immunol. 165: 4783-4786.
40. + cell subsets and different mechanisms. Transplantation 78: 660-667.
41. Mitani, Y., A. Takaoka, S. H. Kim, Y. Kato, T. Yokochi, N. Tanaka, and T. Taniguchi. 2001. Cross talk of the interferon-α/β signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 6: 631-640.
42. Kato, H., O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. Matsui, S. Uematsu, A. Jung, T. Kawai, K. J. Ishii, et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105.
43. Jones, N. D., S. E. Turvey, A. Van Maurik, M. Hara, C. I. Kingsley, C. H. Smith, A. L. Mellor, P. J. Morris, and K. J. Wood. 2001. Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J. Immunol. 166: 2824-2830.
44. Phillips, N. E., T. G. Markees, J. P. Mordes, D. L. Greiner, and A. A. Rossini. 2003. Blockade of CD40-mediated signaling is sufficient for inducing islet but not skin transplantation tolerance. J. Immunol. 170: 3015-3023.
45. Tailor, P., T. Tamura, and K. Ozato. 2006. IRF family proteins and type I interferon induction in dendritic cells. Cell Res. 16: 134-140.
46. Hahm, B., M. J. Trifilo, E. I. Zuniga, and M. B. Oldstone. 2005. Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling. Immunity 22: 247-257.
47. + T cells. Immunol. Rev. 211: 81-92.
48. Gil, M. P., R. Salomon, J. Louten, and C. A. Biron. 2006. Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo. Blood 107: 987-993.
49. McNally, J. M., C. C. Zarozinski, M. Y. Lin, M. A. Brehm, H. D. Chen, and R. M. Welsh. 2001. Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses. J. Virol. 75: 5965-5976.
50. Curtsinger, J. M., J. O. Valenzuela, P. Agarwal, D. Lins, and M. F. Mescher. 2005. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174: 4465-4469.
51. Kolumam, G. A., S. Thomas, L. J. Thompson, J. Sprent, and K. Murali-Krishna. 2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202: 637-650.
52. Bahl, K., S. K. Kim, C. Calcagno, D. Ghersi, R. Puzone, F. Celada, L. K. Selin, and R. M. Welsh. 2006. IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections. J. Immunol. 176: 4284-4295.
53. Palmer, S. M., L. H. Burch, R. D. Davis, W. F. Herczyk, D. N. Howell, N. L. Reinsmoen, and D. A. Schwartz. 2003. The role of innate immunity in acute allograft rejection after lung transplantation. Am. J. Respir. Crit. Care Med. 168: 628-632.
54. Palmer, S. M., L. H. Burch, A. J. Trindade, R. D. Davis, W. F. Herczyk, N. L. Reinsmoen, and D. A. Schwartz. 2005. Innate immunity influences longterm outcomes after human lung transplant. Am. J. Respir. Crit. Care Med. 171: 780-785.
55. Ducloux, D., M. Deschamps, M. Yannaraki, C. Ferrand, J. Bamoulid, P. Saas, A. Kazory, J. M. Chalopin, and P. Tiberghien. 2005. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int. 67: 2454-2461.
56. Palmer, S. M., L. H. Burch, S. Mir, S. R. Smith, P. C. Kuo, W. F. Herczyk, N. L. Reinsmoen, and D. A. Schwartz. 2006. Donor polymorphisms in Toll-like receptor-4 influence the development of rejection after renal transplantation. Clin. Transplant. 20: 30-36.